Protease inhibitor-based therapy is associated with decreased HIV- related health care costs in men treated at a veterans administration hospital

Philip Keiser, Mary Beth Kvanli, Dianna Turner, Joan Reisch, James W. Smith, Naiel Nassar, Clark Gregg, Daniel Skiest

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: Protease inhibitor (PI) therapy for HIV infection is associated with decreased rates of opportunistic infections and death. Statistical models predict that decreased complications will be associated with decreased hospitalization costs. A recent report suggested that the decrease in the HIV hospitalization costs were offset by increases in demand for outpatient services. We performed a study of hospital use and HIV- associated health care costs in our center to determine the following: whether PI therapy is associated with decreased inpatient use; whether PI therapy is associated with decreased outpatient use and costs; whether decreased HIV health care costs are associated with increased use of nucleoside analogues. Methods: The Dallas Veteran Affairs Medical Center provides comprehensive inpatient and outpatient HIV care and thus can evaluate the relation between inpatient and outpatient costs. The mean monthly number of hospital days, Infectious Diseases clinic visits, emergency department visits, other outpatient clinic visits, inpatient costs, outpatient costs, and PI costs were determined from January 1, 1995 through July 31, 1997. This time period was then divided into three intervals. Comparisons of PI use and HIV-related health care costs were during the three intervals was performed using analysis of variance (ANOVA). Significant differences between the baseline characteristics were further analyzed through multiple linear regression. Results: A decrease in hospital days, and all outpatient visits including emergency visits, and HIV clinic visits was determined. No difference was found in the rate of use of other outpatient services. The per patient costs of HIV care decreased from a monthly average of $1905 U.S. in the first interval to $1122 U.S. in the last interval (p < .01). Linear regression demonstrated an inverse relation between PI use and total HIV costs (B = -0.67, p = .00, adjusted R2 = 0.52) but no relation between nucleoside use, stage of disease or financial class. Conclusions: PI therapy is associated with decreased hospital days and use of outpatient services. Total patient costs decreased, but a concomitant rise in outpatient costs took place. This increase was primarily a result of increased costs of acquiring PI. Increases in the number of nucleoside agents prescribed were not associated with decreased costs.

Original languageEnglish (US)
Pages (from-to)28-33
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume20
Issue number1
StatePublished - Jan 1 1999

Fingerprint

Veterans Hospitals
United States Department of Veterans Affairs
Protease Inhibitors
Health Care Costs
HIV
Costs and Cost Analysis
Ambulatory Care
Outpatients
Inpatients
Therapeutics
Nucleosides
Linear Models
Hospitalization
HIV Protease Inhibitors
Opportunistic Infections
Statistical Models
Veterans
Ambulatory Care Facilities
HIV Infections
Communicable Diseases

Keywords

  • HIV-related health costs
  • Protease inhibitor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this

Protease inhibitor-based therapy is associated with decreased HIV- related health care costs in men treated at a veterans administration hospital. / Keiser, Philip; Kvanli, Mary Beth; Turner, Dianna; Reisch, Joan; Smith, James W.; Nassar, Naiel; Gregg, Clark; Skiest, Daniel.

In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 20, No. 1, 01.01.1999, p. 28-33.

Research output: Contribution to journalArticle

@article{ee0cedd6bf294afb9ab25c9a4e934045,
title = "Protease inhibitor-based therapy is associated with decreased HIV- related health care costs in men treated at a veterans administration hospital",
abstract = "Background: Protease inhibitor (PI) therapy for HIV infection is associated with decreased rates of opportunistic infections and death. Statistical models predict that decreased complications will be associated with decreased hospitalization costs. A recent report suggested that the decrease in the HIV hospitalization costs were offset by increases in demand for outpatient services. We performed a study of hospital use and HIV- associated health care costs in our center to determine the following: whether PI therapy is associated with decreased inpatient use; whether PI therapy is associated with decreased outpatient use and costs; whether decreased HIV health care costs are associated with increased use of nucleoside analogues. Methods: The Dallas Veteran Affairs Medical Center provides comprehensive inpatient and outpatient HIV care and thus can evaluate the relation between inpatient and outpatient costs. The mean monthly number of hospital days, Infectious Diseases clinic visits, emergency department visits, other outpatient clinic visits, inpatient costs, outpatient costs, and PI costs were determined from January 1, 1995 through July 31, 1997. This time period was then divided into three intervals. Comparisons of PI use and HIV-related health care costs were during the three intervals was performed using analysis of variance (ANOVA). Significant differences between the baseline characteristics were further analyzed through multiple linear regression. Results: A decrease in hospital days, and all outpatient visits including emergency visits, and HIV clinic visits was determined. No difference was found in the rate of use of other outpatient services. The per patient costs of HIV care decreased from a monthly average of $1905 U.S. in the first interval to $1122 U.S. in the last interval (p < .01). Linear regression demonstrated an inverse relation between PI use and total HIV costs (B = -0.67, p = .00, adjusted R2 = 0.52) but no relation between nucleoside use, stage of disease or financial class. Conclusions: PI therapy is associated with decreased hospital days and use of outpatient services. Total patient costs decreased, but a concomitant rise in outpatient costs took place. This increase was primarily a result of increased costs of acquiring PI. Increases in the number of nucleoside agents prescribed were not associated with decreased costs.",
keywords = "HIV-related health costs, Protease inhibitor",
author = "Philip Keiser and Kvanli, {Mary Beth} and Dianna Turner and Joan Reisch and Smith, {James W.} and Naiel Nassar and Clark Gregg and Daniel Skiest",
year = "1999",
month = "1",
day = "1",
language = "English (US)",
volume = "20",
pages = "28--33",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Protease inhibitor-based therapy is associated with decreased HIV- related health care costs in men treated at a veterans administration hospital

AU - Keiser, Philip

AU - Kvanli, Mary Beth

AU - Turner, Dianna

AU - Reisch, Joan

AU - Smith, James W.

AU - Nassar, Naiel

AU - Gregg, Clark

AU - Skiest, Daniel

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Background: Protease inhibitor (PI) therapy for HIV infection is associated with decreased rates of opportunistic infections and death. Statistical models predict that decreased complications will be associated with decreased hospitalization costs. A recent report suggested that the decrease in the HIV hospitalization costs were offset by increases in demand for outpatient services. We performed a study of hospital use and HIV- associated health care costs in our center to determine the following: whether PI therapy is associated with decreased inpatient use; whether PI therapy is associated with decreased outpatient use and costs; whether decreased HIV health care costs are associated with increased use of nucleoside analogues. Methods: The Dallas Veteran Affairs Medical Center provides comprehensive inpatient and outpatient HIV care and thus can evaluate the relation between inpatient and outpatient costs. The mean monthly number of hospital days, Infectious Diseases clinic visits, emergency department visits, other outpatient clinic visits, inpatient costs, outpatient costs, and PI costs were determined from January 1, 1995 through July 31, 1997. This time period was then divided into three intervals. Comparisons of PI use and HIV-related health care costs were during the three intervals was performed using analysis of variance (ANOVA). Significant differences between the baseline characteristics were further analyzed through multiple linear regression. Results: A decrease in hospital days, and all outpatient visits including emergency visits, and HIV clinic visits was determined. No difference was found in the rate of use of other outpatient services. The per patient costs of HIV care decreased from a monthly average of $1905 U.S. in the first interval to $1122 U.S. in the last interval (p < .01). Linear regression demonstrated an inverse relation between PI use and total HIV costs (B = -0.67, p = .00, adjusted R2 = 0.52) but no relation between nucleoside use, stage of disease or financial class. Conclusions: PI therapy is associated with decreased hospital days and use of outpatient services. Total patient costs decreased, but a concomitant rise in outpatient costs took place. This increase was primarily a result of increased costs of acquiring PI. Increases in the number of nucleoside agents prescribed were not associated with decreased costs.

AB - Background: Protease inhibitor (PI) therapy for HIV infection is associated with decreased rates of opportunistic infections and death. Statistical models predict that decreased complications will be associated with decreased hospitalization costs. A recent report suggested that the decrease in the HIV hospitalization costs were offset by increases in demand for outpatient services. We performed a study of hospital use and HIV- associated health care costs in our center to determine the following: whether PI therapy is associated with decreased inpatient use; whether PI therapy is associated with decreased outpatient use and costs; whether decreased HIV health care costs are associated with increased use of nucleoside analogues. Methods: The Dallas Veteran Affairs Medical Center provides comprehensive inpatient and outpatient HIV care and thus can evaluate the relation between inpatient and outpatient costs. The mean monthly number of hospital days, Infectious Diseases clinic visits, emergency department visits, other outpatient clinic visits, inpatient costs, outpatient costs, and PI costs were determined from January 1, 1995 through July 31, 1997. This time period was then divided into three intervals. Comparisons of PI use and HIV-related health care costs were during the three intervals was performed using analysis of variance (ANOVA). Significant differences between the baseline characteristics were further analyzed through multiple linear regression. Results: A decrease in hospital days, and all outpatient visits including emergency visits, and HIV clinic visits was determined. No difference was found in the rate of use of other outpatient services. The per patient costs of HIV care decreased from a monthly average of $1905 U.S. in the first interval to $1122 U.S. in the last interval (p < .01). Linear regression demonstrated an inverse relation between PI use and total HIV costs (B = -0.67, p = .00, adjusted R2 = 0.52) but no relation between nucleoside use, stage of disease or financial class. Conclusions: PI therapy is associated with decreased hospital days and use of outpatient services. Total patient costs decreased, but a concomitant rise in outpatient costs took place. This increase was primarily a result of increased costs of acquiring PI. Increases in the number of nucleoside agents prescribed were not associated with decreased costs.

KW - HIV-related health costs

KW - Protease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0032900149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032900149&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 28

EP - 33

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 1

ER -